Thuringian Innovation Award
The prize is the second highly endowed award that oncgnostics received this year for their innovative GynTect test: Back in April, the company received the IQ Innovation Award Central Germany in the "Life Sciences" cluster.
The molecular biological test can be used to clarify at an early stage whether a patient with abnormal findings in the Pap smear test or a human papillomavirus (HPV) infection develops or has cervical cancer (cervix carcinoma) that needs to be treated. GynTect provides quick and reliable test results and thus gives affected women certainty just as fast. This makes risk assessment for early cervical cancer detection so much easier. Unnecessary, premature surgery can be avoided, and the chances of early, successful therapy measures can be increased.
Since October, the quick test has been further developed in the ASSURER project at the research campus: In cooperation with other InfectoGnostics partners, GynTect is to be be expanded into a fully automated test system
The award ceremony took place in front of about 400 guests from business, politics, and science in the Neue Weimarhalle congress centre. The Innovation Award Thuringia - with 10,000 euros, one of Germany's most highly endowed innovation awards - honours innovative, marketable products, processes, services, and research excellence in four categories. A total of 70 firms applied for the innovation award. oncgnostics GmbH was able to prevail against 13 top-class competitors in the category "Light & Life". In this category, novelties from the fields of energy, environment, optical technologies, medical technology, and biotechnology were awarded prizes.
Cervical cancer is caused by an infection with HP viruses, which are transmitted through sexual intercourse, among other things. Therefore, in most cases, infection occurs well before the age of 30. The sooner a conspicuous malignant change in the cervix's tissue or a precancerous stage is detected, the better the chances of successful treatment and patient recovery. Only around 50 per cent of women participate annually in the Pap smear test currently used for early detection.
Worldwide, there is a very high demand for reliable screening and clarification tests. GynTect is meant to help reliably diagnose cervical cancer and its precursors, avoid unnecessary surgery and detect malignant tissue changes in time.
The clarification test is already approved for laboratory use throughout Europe. CE approval for the test was granted in 2015. So far, there are distribution partnerships in China and India. Further international cooperations are in preparation.